ISSN: 1859 - 2872
Results of external quality assessment for target gene mutation in haematological diseases
Main Article Content
Keywords
Abstract
Summary
Objective: The aim of this script is to report 108 Military Central Hospital’s current external quality assessment (EQA) results of molecular assays used for identification of common leukemia related fusion genes: AML1-ETO, PML-RARA, Tel-AML1, BCR-ABL, CBFB-MYH11 and somatic mutations: Jak2, NPM-1, FLT3. Subject and method: Blind samples from UK-NEQAS were provided for detecting of fusion genes AML1-ETO, PML-RARA, Tel-AML1, BCR-ABL, CBFB-MYH11, and somatic mutation Jak2 V617F, NPM-1, FLT3 by the 108 Military Central Hospital established assays. Result: All qualitative diagnostics results gained by institutional approach were consensus to that provided by United Kindom National External Quality Assessment Survice (UK-NEQAS). Whereas, the quantification of samples with more than 1% mutational load was also at hight level of agreement to that of UK-NEQAS. Conclusion: 108 Military Central Hospital institutional molecular assays meet the UK-NEQAS’s quality standards for identification of common genetics lesions in leukemia patients.
Keywords: Haematological diseases, gene mutation.
Article Details
References
2. Branford S et al (2008) Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 112(8): 3330-3338.
3. Vigneri P et al (2017) High BCR-ABL/GUS(IS) levels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib. Clin Cancer Res 23(23): 7189-7198.
4. Zhang J et al (2018) Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: Results from a multicenter study of the Chinese CML alliance. Blood Cancer J 8(7): 61.
Article Sidebar
